Araya Negash, DO
Interventional Cardiology · Grand Rapids, MINPI 1669793253
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,000 of the $7,315 with a category attached, or 68.4%. Siemens Medical Solutions USA, Inc. accounts for 68.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $5,611 and has fallen 85.4% since, to $822 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MI, where the typical reported total is $6,857.
Across 53 payments — averaging $138.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Siemens Medical Solutions USA, Inc.$5K
- Abbott$882
- Medtronic$379
- Shockwave Medical, Inc$371
- Boston Scientific$360
- Abiomed$132
- plus $191 from 7 others
Across 39 payments — averaging $20,530 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$801K
What the payments were for
- Consulting fees$5,00068%
- Food & beverage$2,31532%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Siemens Medical Solutions USA, Inc. | 1 | $5,000 |
| Abbott | 7 | $882 |
| Medtronic | 8 | $379 |
| Shockwave Medical, Inc | 8 | $371 |
| Boston Scientific | 14 | $360 |
| Abiomed | 7 | $132 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $40 |
| Chiesi USA, Inc. | 1 | $32 |
| Edwards Lifesciences | 1 | $31 |
| Cardiovascular Systems Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,315 in reported general payments places this provider in the 50th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 161 | $182,783 |
| EntrestoSacubitril/Valsartan | 73 | $85,132 |
| JardianceEmpagliflozin | 40 | $46,907 |
| FarxigaDapagliflozin Propanediol | 46 | $39,247 |
| BrilintaTicagrelor | 40 | $31,880 |
| XareltoRivaroxaban | 17 | $24,113 |
| Repatha SureclickEvolocumab | 25 | $17,833 |
| Metoprolol Succinate | 312 | $8,533 |
| Atorvastatin Calcium | 344 | $6,990 |
| Rosuvastatin Calcium | 175 | $4,167 |
| Ezetimibe | 111 | $4,044 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 137 | $3,083 |
| Carvedilol | 143 | $2,446 |
| Ranolazine ErRanolazine | 31 | $2,373 |
| ClopidogrelClopidogrel Bisulfate | 110 | $2,041 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $14 | $85,13273 claims |
| Boehringer IngelheimJardiance | $23 | $46,90740 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Grand Rapids
- Duane BerkompasGrand Rapids$159K
- David WohnsGrand Rapids$129K
- William MerhiGrand Rapids$114K
- Timothy JosephGrand Rapids$17K
- Devraj SukulGrand Rapids$13K
- Cody CarterGrand Rapids$12K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.